Title |
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1
|
---|---|
Published in |
Cancer Immunology, Immunotherapy, August 2013
|
DOI | 10.1007/s00262-013-1466-y |
Pubmed ID | |
Authors |
Yibing Xu, Jianping Sun, Michael A. Sheard, Hung C. Tran, Zesheng Wan, Wei Yao Liu, Shahab Asgharzadeh, Richard Sposto, Hong Wei Wu, Robert C. Seeger |
Abstract |
Treatment for children with high-risk neuroblastoma with anti-disialoganglioside mAb ch14.18, IL-2, and GM-CSF plus 13-cis-retinoic acid after myeloablative chemotherapy improves survival, but 40 % of patients still relapse during or after this therapy. The microenvironment of high-risk neuroblastoma tumors includes macrophages, IL-6, and TGFβ1. We hypothesized that this microenvironment suppresses anti-tumor functions of natural killer (NK) cells and that lenalidomide, an immune-modulating drug, could overcome suppression. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Hungary | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 2 | 4% |
Unknown | 47 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 18% |
Student > Doctoral Student | 7 | 14% |
Student > Ph. D. Student | 7 | 14% |
Student > Bachelor | 5 | 10% |
Student > Master | 4 | 8% |
Other | 6 | 12% |
Unknown | 11 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 31% |
Agricultural and Biological Sciences | 9 | 18% |
Biochemistry, Genetics and Molecular Biology | 5 | 10% |
Immunology and Microbiology | 5 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Other | 2 | 4% |
Unknown | 11 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2013.
All research outputs
#18,345,822
of 22,719,618 outputs
Outputs from Cancer Immunology, Immunotherapy
#2,428
of 2,889 outputs
Outputs of similar age
#149,548
of 200,133 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#12
of 13 outputs
Altmetric has tracked 22,719,618 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,889 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,133 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.